Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Free Cash Flow (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Free Cash Flow for 2 consecutive years, with -$17.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 37.24% to -$17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$62.3 million through Dec 2025, up 8.14% year-over-year, with the annual reading at -$62.3 million for FY2025, 8.14% up from the prior year.
  • Free Cash Flow hit -$17.3 million in Q4 2025 for Silence Therapeutics, down from -$10.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.5 million in Q2 2024 to a low of -$27.5 million in Q4 2024.